Treatment of Insomnia and Anxiety in Alcohol Withdrawal
Benzodiazepines are the gold standard treatment for managing both anxiety and insomnia during alcohol withdrawal, with symptom-triggered dosing preferred over fixed schedules. 1
Acute Withdrawal Phase (First 10-14 Days)
First-Line Pharmacotherapy: Benzodiazepines
Benzodiazepines remain the cornerstone treatment because they effectively reduce withdrawal symptoms while preventing life-threatening complications including seizures and delirium tremens. 1
Choice of benzodiazepine depends on liver function and patient age:
Long-acting agents (diazepam, chlordiazepoxide): Provide superior protection against seizures and delirium tremens in patients with normal liver function 1
Short/intermediate-acting agents (lorazepam, oxazepam): Safer in elderly patients and those with hepatic dysfunction 1
Dosing strategy: Use symptom-triggered regimens guided by CIWA-Ar scores rather than fixed schedules to prevent drug accumulation. 1 Treat when CIWA-Ar >8 (moderate withdrawal) or ≥15 (severe withdrawal). 1
Critical limitation: Discontinue benzodiazepines after 10-14 days maximum due to abuse potential, particularly high in patients with alcohol use disorder. 1
Alternative Acute Agents
Gabapentin shows efficacy for mild to moderate withdrawal symptoms and may be superior to lorazepam in patients with multiple previous withdrawal episodes, with reduced sleep disturbances and less rebound symptoms. 2, 3
Carbamazepine can treat mild symptoms and serves as an adjunctive or alternative therapy for moderate to severe cases. 3
Post-Acute Insomnia (After 4+ Weeks of Sobriety)
First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)
CBT-I is the recommended first-line treatment for persistent insomnia in alcohol use disorder with high-level evidence supporting its efficacy. 4, 5, 6 This approach provides long-lasting benefits without worsening drinking outcomes. 5
CBT-I can be delivered through multiple modalities: individual/group therapy, telephone/web-based modules, or self-help materials. 7 Sleep efficiency improvements are consistently demonstrated across studies. 6
Pharmacotherapy for Persistent Insomnia (When CBT-I Insufficient or Unavailable)
Use shared decision-making when adding medications, discussing that they work faster than CBT-I but generally only work while taken. 7, 5
Medications with moderate evidence in AUD populations:
- Gabapentin (immediate release): Moderate evidence for efficacy 4
- Mirtazapine: Moderate evidence, sedating antidepressant 4
- Quetiapine: Moderate evidence, though off-label use 4
Medications with low evidence:
- Trazodone: Low evidence but commonly used 4
- Melatonin/melatonin agonists: Low evidence 4
- Topiramate: Low evidence for insomnia specifically, though shows promise for reducing heavy drinking 1, 4
Avoid benzodiazepines and other GABA-A agonists for chronic insomnia treatment in AUD due to abuse potential and lack of long-term efficacy. 4, 8
Critical Clinical Considerations
Assess for contributing factors before treating: Rule out sleep apnea, periodic limb movement disorder, psychiatric comorbidities, and medication effects through comprehensive evaluation. 5 Polysomnography is indicated when another sleep disorder is suspected or insomnia is treatment-resistant. 5
Monitor patients with severe symptoms or psychiatric comorbidities more closely, as they may require pharmacotherapy while awaiting CBT-I effectiveness (which takes several weeks). 4
Pay particular attention to patients who used alcohol as a sleep aid, as they carry higher relapse risk after stopping treatment. 4
Daily monitoring is essential for outpatients during the first 5 days after last drink to verify symptom improvement and evaluate need for additional treatment. 3